Nowadays, the seek for bilateral prophylactic mastectomy particularly in women with a genetic predisposition for breast cancer (e.g. BRCA-1, BRCA-2, p53) increases and accordingly represents an ideal indication for IBR of any type, knowing that neither adjuvant chemotherapy nor adjuvant radiotherapy will be required (19). Here, TP53 is linked to breast carcinoma.